Although IFN-γ has been proposed for use in other PMN dysfunction disorders, information is lacking about its efficacy in diseases other than CGD, osteopetrosis, hyperimmunoglobulin E syndromes and rare defects in the IL-12/IFN-γ pathways [1,2]. Here, IFNG is linked to chronic granulomatous disease.